{"schema_version":"secwatch.filing_event.v1","accession":"0000771856-25-000022","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.347940+00:00","generated_at":"2026-05-17T06:41:48.850868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology Q1 FY2026 revenue $14.0M; adjusted EBITDA $60K vs $2.0M; CEO Rob Brainin appointed","bullets":["Revenue $14.0M, down from $14.1M YoY; operating loss of $527K vs income of $1.3M.","Adjusted EBITDA fell to $60K from $2.0M; gross margin 43% vs 50%.","Rob Brainin appointed CEO; previously CEO? He signs report as CEO as of Sept 15, 2025.","Cash on hand $10.3M with no debt; net cash from operations $600K."],"urls":{"canonical":"https://secwatch.observer/filing/0000771856-25-000022","json":"https://secwatch.observer/filing/0000771856-25-000022.json","markdown":"https://secwatch.observer/filing/0000771856-25-000022.md","text":"https://secwatch.observer/filing/0000771856-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000077185625000022/0000771856-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000077185625000022/csbr-20250915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:41:48.850868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}